Emerging markets are benefiting from enhanced healthcare infrastructure, boosting access to CMV diagnostics and treatments. Furthermore, advancements in personalized medicine and vaccine development, ...
A four-year-old boy from Oklahoma, born with congenital CMV, experiences the world of sound for the first time after ...
Spytek's shoes for MCMC portray more than his daughter, who passed away at just 21 months old in 2014 after being born with ...
Evaxion’s AI-Immunology™ platform has discovered novel CMV antigens that significantly reduce viral infection in preclinical models EVX-V1 is a next-generation, multi-component vaccine program ...
Congenital cytomegalovirus is the most common nongenetic cause of hearing loss in childhood, yet many parents do not know ...
A comprehensive eight-year study examining audiological outcomes of newborns screened for congenital cytomegalovirus (cCMV) through universal screening demonstrates the critical importance of early ...
CAMBRIDGE, MA / ACCESS Newswire / October 22, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the Company’s ...
Company to discontinue development of mRNA-1647 in congenital CMV Company will continue to evaluate mRNA-1647 in ongoing Phase 2 trial in bone marrow transplant patients Company does not anticipate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback